top of page

NCI-2019-04523

A Phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusions


It's a Phase 1/2 study looking at a drug called IDE196 in patients with certain types of solid tumors. These tumors have mutations in GNAQ/11 or PRKC genes.

Phase 1/2 study: A study that assesses the safety, effectiveness, and how well the treatment works

For more information about the trial, click the link below:

Clinical Trial Site: Columbia


To see all available clinical trials click here.



Recent Posts

See All

NCI-2021-10597

A Phase 1 Open-Label, Dose-Escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients with Locally...

NCI-2022-10927

A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with...

NCT-05753722

An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety,Pharmacokinetics, Pharmacodynamics, and Activity of...

Comments

bottom of page